THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE

(19)

(11)

EP 4 782 065 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 A2)

(48)	Corrigendum issued on:
	21.10.2026 Bulletin 2026/43

(88)	Date of publication A3:
	07.10.2026 Bulletin 2026/41

(43)	Date of publication:
	29.07.2026 Bulletin 2026/31

(21)	Application number: 26170374.8

(22)	Date of filing: 11.09.2020

(51)

International Patent Classification (IPC):

A61K 31/506^(2006.01)

A61P 35/00^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 31/506; A61P 35/00

	C-Sets:
	A61K 31/506, A61K 2300/00;

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

13.09.2019 WO PCT/EP2019/074565

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	20772249.7 / 4028010

(71)	Applicant: The Institute of Cancer Research: Royal Cancer Hospital
	London SW7 3RP (GB)

(72)	Inventor:
	BANERJI, Udai London, SW7 3RP (GB)

(74)	Representative: Hoffmann Eitle
	Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München 81925 München (DE)


	Remarks:
	This application was filed on 02.04.2026 as a divisional application to the application mentioned under INID code 62.


	Remarks:
	Claims filed after the date of filing/ after the date of receipt of the divisional application (Rule 68(4) EPC)

(54)	THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE

(57) This invention relates to methods comprising administering a FAK inhibitor (e.g., VS-6063) in combination with a dual RAF/MEK inhibitor (e.g., CH5126766) that are useful in the treatment of abnormal cell growth, such as cancer, in a subject such as humans.